Meet the Team
Management of the Provis Infusion Clinic
Provis Infusion Clinic was established by a group of health care professionals who are interested in the changing landscape of healthcare delivery in Canada. Our directors have many years of experience in designing, founding and operating health care companies and freestanding clinics in Canada.
Graham Vincent, BPHE, MBA
President, Provis Infusion Clinic
Graham has over 25 years of business management experience in providing patient oriented services in the healthcare industry. He has successfully built and lead several leading healthcare organizations.
Director of Pharmaceutical Services, Provis Infusion Clinic
Ostap has been a pharmacist for 25 years and has been in involved with oncology medication preparation for over 25 years. He has previously worked at Toronto General Hospital (UHN). He also works at the Sunnybrook Regional Cancer Program on an occasional basis and is up to date on new drug developments. He also has worked in the pharmaceutical industry for a major pharmaceutical company in business and product development.
Our Dedicated Staff
Our physician staff consists of three Physicians from emergency medicine and oncology. All infusions are supervised by on-site physician.
Our pharmaceutical team consists of three Pharmacists and three Pharmacy Technicians. Your medications are always mixed on site by a Pharmacy Technician who is supervised by the Pharmacist. All of our medication compounding is done on site to make things as seamless and flexible as possible.
Our helpful and friendly office staff provide efficient and seamless administrative services from first patient contact to completion of treatment. They take pride in anticipating the needs of our patients and referring physicians while ensuring smooth business operations at the clinic.
We recognize the invaluable contribution an experienced nurse can make to the patient experience in intravenous therapies. Our nurses are highly trained and certified in their specialty with many years of experience in patient care. Their compassion and respect for each patient’s individuality has a lasting, positive effect on the well being of our patients.
Why Choose Provis?
- Infusion Services Since 2005
- Over 13,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
15 Year Anniversary!The Provis Infusion Clinic is please to announce that August 2020 marks the 15 anniversary of the Provis Infusion Clinic. We are looking forward to the next 15 years of providing high quality infusion services.
COVID 19 TrialProvis is pleased to partner with University Health Network, University of Toronto, EMS services and Police Services on a Phase 3 Clinical Trial focusing on COVUD 19. Called 'Cobra' the trial will look at the effectiveness of the vaccine BCG in the minimization of the COVID symptoms and the contraction of the virus.
New MedicationsVenofer™ (Iron Sucrose) Onivyde™ (Irinotecan liposome for injection) Tecentriq™ (Atezolizumab) Renflexis™ (Infliximab) Yondelis™ (Trabectedin) Yervoy™ (Ipilimumab)
Kyprolis™ (Carfilzomib) receives Health Canada approval.Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
Opdivo™ (Nivolumab) receives Health Canada approval.Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
Update – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane® Kadcyla® Tecentriq® Yervoy® Opdivo® Patients: Provis participates in the Roche Patient Assistance Program, the , the OnCare Program, the Merck Care Oncology, and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Tecentriq®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Opdivo® ® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.